Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supply Side East In Brief

This article was originally published in The Tan Sheet

Executive Summary

Sigma-tau teas: Livingtonics specialty tea beverages fortified with 2g to 4g of supplement ingredients will launch by the end of the year, Sigma-tau HeathScience said at Supply Side East Tradeshow & Conference in Baltimore, Md. May 5. Three varieties of Livingtonics drinks cater to different functions: ZenBrew for the mind includes acetyl L-carnitine and CoQ10 to "support cognitive health," ResveraCarn for the heart contains D-ribose and resveratrol to "help support vascular functions" and InTouch for sports enhancement offers D-ribose and creatine monohydrate to "support the metabolism of fat and production of energy," according to product labeling. The drinks are aimed at high-end health club and health food store customers and will retail for around $4, the New York-based firm says...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel